Literature DB >> 17554704

Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.

Tihana Bicanic1, Graeme Meintjes, Robin Wood, Madeleine Hayes, Kevin Rebe, Linda-Gail Bekker, Thomas Harrison.   

Abstract

In a prospective observational study of 54 patients with human immunodeficiency virus-associated cryptococcal meningitis, the early fungicidal activity of amphotericin B (1 mg/kg/day) was significantly greater than that of fluconazole (400 mg/day). Compared with antiretroviral therapy-naive patients, patients developing cryptococcal meningitis while already receiving antiretroviral therapy had lower baseline fungal burdens and a longer median duration of survival, but there were no differences observed in fungal clearance, cerebrospinal fluid proinflammatory cytokines, or 10-week mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554704     DOI: 10.1086/518607

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  142 in total

Review 1.  Management of cryptococcal meningitis in sub-saharan Africa.

Authors:  Arthur Jackson; Mina C Hosseinipour
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Companion drugs for amphotericin B in cryptococcal meningitis: flucytosine, fluconazole, or...Nothing?

Authors:  John Bennett
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

3.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

4.  Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.

Authors:  Renee Donahue Carlson; Melissa A Rolfes; Kate E Birkenkamp; Noeline Nakasujja; Radha Rajasingham; David B Meya; David R Boulware
Journal:  Metab Brain Dis       Date:  2014-01-09       Impact factor: 3.584

5.  Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain.

Authors:  A Pool; L Lowder; Y Wu; K Forrester; J Rumbaugh
Journal:  J Neurovirol       Date:  2013-06-04       Impact factor: 2.643

6.  Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.

Authors:  Taseera Kabanda; Mark J Siedner; Jeffrey D Klausner; Conrad Muzoora; David R Boulware
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

7.  Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.

Authors:  Rachel M Wake; Nelesh P Govender; Tanvier Omar; Carolina Nel; Ahmad Haeri Mazanderani; Aaron S Karat; Nazir A Ismail; Caroline T Tiemessen; Joseph N Jarvis; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

Review 8.  Antifungal clinical trials and guidelines: what we know and do not know.

Authors:  Peter G Pappas
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

9.  The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.

Authors:  R Mdodo; K Brown; E Omonge; W Jaoko; J Baddley; P Pappas; M Colette Kempf; I Aban; S Odera; A Suleh; P E Jolly
Journal:  East Afr Med J       Date:  2010-12

10.  Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.

Authors:  Josephine V J Lightowler; Graham S Cooke; Portia Mutevedzi; Richard J Lessells; Marie-Louise Newell; Martin Dedicoat
Journal:  PLoS One       Date:  2010-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.